nocturno forte 7.5
unipharm ltd, israel - zopiclone - tablets - zopiclone 7.5 mg - zopiclone - zopiclone - hypnotic when the disorder of insomnia is severe and disabling.
nocturno 3.75
unipharm ltd, israel - zopiclone - tablets - zopiclone 3.75 mg - zopiclone - zopiclone - hypnotic.
optilast
megapharm ltd - azelastine hydrochloride - eye drops, solution - azelastine hydrochloride 0.05 % - azelastine - azelastine - symptomatic treatment and prevention of seasonal allergic conjunctivitis.
amoxy care forte 250 suspension
vitamed pharmaceutical industries ltd - amoxicillin as trihydrate - powder for suspension - amoxicillin as trihydrate 250 mg / 5 ml - amoxicillin - • for the treatment of infections caused by bacteria susceptible to amoxicillin.• intended for the prevention of bacterial infections in patients who are at risk for developing bacterial endocarditis.
rosuvastatin sandoz 10 mg
novartis israel ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 10 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.
rosuvastatin sandoz 10 mg
novartis israel ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 10 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.
rosuvastatin sandoz 20 mg
novartis israel ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 20 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.
rosuvastatin sandoz 20 mg
novartis israel ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 20 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.
rosuvastatin sandoz 40 mg
novartis israel ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 40 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.
rosuvastatin sandoz 40 mg
novartis israel ltd - rosuvastatin as calcium - film coated tablets - rosuvastatin as calcium 40 mg - rosuvastatin - primary hypercholesterolaemia (type iia including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type iib) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise weight reduction) is inadequate. homozygous familial hypercholesterolaemia as adjunct to diet and other lipid lowering treatments (e.g. ldl apheresis) or if such treatments are not appropriate.